{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:06:56Z","timestamp":1782961616765,"version":"3.54.5"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,7]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Immune-checkpoint inhibitors have emerged as a frontline treatment for a growing list of malignancies. Immunotherapy-induced bullous pemphigoid (BP) is a rare dermatological immune-related adverse event of immune-checkpoint inhibitor therapy immune-checkpoint inhibitor therapy. We report a case of immunotherapy-associated BP, with lesions presenting in a photodistribution. This case report aims to emphasize the early recognition of rare clinical manifestations induced by immunotherapy to improve patient prognosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>The patient was a 77-year-old man with a history of right upper lung squamous cell carcinoma on sintilimab (anti-programmed cell death protein-1 [PD-1]) for over a year. After 12 months of initiation of PD-1 inhibitors, nonspecific cutaneous eruption appeared on his head, face, and extremities, mostly pruritic eczematous dermatitis with papules and plaques. The time to development of bullae after medication initiation was 16 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Sintilimab-induced BP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>Oral prednisone was gradually tapered to discontinuation following intravenous methylprednisolone; the skin lesions have basically recovered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Follow-up for 19 months showed no recurrence of the skin lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case report emphasizes that the clinical manifestations of BP induced by PD-1\/programmed death ligand-1 inhibitors can be diverse. Dermatologists need to increase their awareness of BP caused by PD-1\/programmed death ligand-1 inhibitors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000041448","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:00:31Z","timestamp":1739217631000},"page":"e41448","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Sintilimab-induced photodistributed bullous pemphigoid: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4728-9126","authenticated-orcid":false,"given":"Wenjuan","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hangzhou Children\u2019s Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5413-5594","authenticated-orcid":false,"given":"Su","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Shen","sequence":"additional","affiliation":[{"name":"Haining Maternity and Child Health Care Hospital, Jiaxing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250210","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy.","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"R2-20250210","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events.","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R3-20250210","doi-asserted-by":"crossref","first-page":"e35659","DOI":"10.1097\/MD.0000000000035659","article-title":"Sintilimab-induced erythema multiforme drug eruption in the treatment of sigmoid colon cancer: a case report and literature review.","volume":"102","author":"Zhang","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R4-20250210","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaad.2019.01.077","article-title":"Incidence and risk of developing photosensitivity with targeted anticancer therapies.","volume":"81","author":"Ciccolini","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R5-20250210","first-page":"adv00335","article-title":"Photosensitive dermatitis induced by nivolumab\/ipilimumab combination therapy in a patient with malignant melanoma.","volume":"100","author":"Sakaguchi","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R6-20250210","doi-asserted-by":"crossref","first-page":"e12924","DOI":"10.1111\/dth.12924","article-title":"A case of atezolizumab-induced photodistributed bullous pemphigoid.","volume":"32","author":"Leavitt","year":"2019","journal-title":"Dermatol Ther"},{"key":"R7-20250210","first-page":"487","article-title":"Drug - induced bullous pemphigoid.","volume":"53","author":"Wang","year":"2020","journal-title":"Chin J Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:00:35Z","timestamp":1739217635000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041448","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}